TScan Therapeutics (NASDAQ:TCRX) Posts Earnings Results, Beats Estimates By $0.02 EPS

TScan Therapeutics (NASDAQ:TCRX) announced its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02, FiscalAI reports. The business had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.88 million. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.

TScan Therapeutics Stock Down 0.4%

Shares of TCRX opened at $0.77 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.65 and a current ratio of 6.65. TScan Therapeutics has a 52 week low of $0.72 and a 52 week high of $2.57. The stock has a market capitalization of $50.32 million, a price-to-earnings ratio of -0.80 and a beta of 1.06. The stock has a fifty day moving average of $0.91 and a 200-day moving average of $1.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its position in TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in TScan Therapeutics by 8.5% in the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after buying an additional 22,642 shares during the period. Marshall Wace LLP bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $78,000. Qube Research & Technologies Ltd acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth approximately $99,000. Finally, Jane Street Group LLC bought a new stake in shares of TScan Therapeutics in the 2nd quarter valued at $309,000. 82.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TCRX has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a report on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Finally, Benchmark reaffirmed a “buy” rating on shares of TScan Therapeutics in a research note on Thursday. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, TScan Therapeutics has a consensus rating of “Hold” and an average price target of $6.00.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.